Intellicell Biosciences Inc (SVFC) financial statements (2021 and earlier)
Company profile
| Business Address |
30 EAST 76TH STREET, 6TH FLOOR NEW YORK, NY 10021 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 10 | |||
| Cash and cash equivalents | 10 | |||
| Receivables | 285 | |||
| Other current assets | 9 | ✕ | ||
| Total current assets: | 9 | 296 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 2,670 | 2,797 | ||
| Restricted cash and investments | 650 | |||
| Other undisclosed noncurrent assets | 534 | 193 | ||
| Total noncurrent assets: | 3,205 | 3,640 | ||
| TOTAL ASSETS: | 3,214 | 3,935 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities, including: | 2,609 | 2,162 | ||
| Accounts payable | 2,021 | 1,377 | ||
| Accrued liabilities | 42 | |||
| Employee-related liabilities | 434 | 274 | ||
| Other undisclosed accounts payable and accrued liabilities | 154 | 470 | ||
| Debt | 841 | 1,609 | ||
| Due to related parties | 1,115 | |||
| Other undisclosed current liabilities | 5,838 | 2,198 | ||
| Total current liabilities: | 9,288 | 7,083 | ||
| Noncurrent Liabilities | ||||
| Other undisclosed noncurrent liabilities | 3,775 | 987 | ||
| Total noncurrent liabilities: | 3,775 | 987 | ||
| Total liabilities: | 13,063 | 8,070 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent, including: | (9,849) | (4,135) | ||
| Common stock | 92 | 59 | ||
| Additional paid in capital | 38,961 | 33,568 | ||
| Accumulated deficit | (48,903) | (37,763) | ||
| Other undisclosed stockholders' equity attributable to parent | 1 | 1 | ||
| Total stockholders' equity: | (9,849) | (4,135) | ||
| TOTAL LIABILITIES AND EQUITY: | 3,214 | 3,935 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Revenues (Revenue, Net) | 535 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (300) | (466) | |
| Gross profit: | (300) | 69 | |
| Operating expenses | (5,521) | (14,940) | |
| Other undisclosed operating income | 300 | ||
| Operating loss: | (5,521) | (14,872) | |
| Nonoperating expense | (5,620) | (10,720) | |
| Investment income, nonoperating | 2,788 | (13,804) | |
| Interest and debt expense | (2,527) | 213 | |
| Loss from continuing operations before equity method investments, income taxes: | (13,668) | (25,378) | |
| Other undisclosed income from continuing operations before income taxes | 2,527 | 21,226 | |
| Net loss available to common stockholders, diluted: | (11,141) | (4,152) | |
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net loss: | (11,141) | (4,152) | |
| Comprehensive loss, net of tax, attributable to parent: | (11,141) | (4,152) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.